Diabetes drug Lyxumia effective in late-stage trials

10/2/2012 | Reuters

Data from late-stage studies show that Sanofi's diabetes drug candidate Lyxumia, or lixisenatide, can reduce blood glucose and slow food passage after a meal when combined with other diabetes treatments, the drugmaker said. Lyxumia is awaiting European approval and will be submitted for FDA approval in December.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC